Welcome to our dedicated page for Evogene news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on Evogene stock.
Evogene Ltd. reports developments as a computational chemistry company focused on generative design of small molecules for pharmaceutical and agricultural applications. Its recurring updates center on ChemPass AI™, a proprietary generative AI platform used to explore chemical space and optimize small-molecule candidates across multiple parameters.
Company news also covers financial results, strategic refocusing around ChemPass AI™, collaborations in drug discovery and ag-chemical development, and subsidiary activity. Reported subsidiary themes include Casterra's castor seed varieties and castor farming systems for bio-based industries, AgPlenus work on novel herbicides and fungicides, Biomica microbiome-based therapeutics, and Nasdaq listing-compliance matters for EVGN ordinary shares.
Lavie Bio Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), has announced a distribution agreement with United Agronomy for its microbial inoculant product LAV.211. The agreement aims to enhance the commercialization of LAV.211 in North Dakota, targeting the 2022 spring wheat season. LAV.211 is designed to improve nutrient uptake and increase crop yield while promoting environmental sustainability. Initial testing has shown positive results, and both companies expect this partnership to benefit local farmers and enhance profitability.
Evogene Ltd. (NASDAQ: EVGN) announced that President and CEO Ofer Haviv will participate in a "Fireside Chat" at the Cantor Virtual Global Healthcare Conference from September 27-30, 2021. The interview will take place on September 28, 2021, at 10:40 am EST. Haviv will discuss Evogene's innovative technologies and product development strategies across its subsidiaries. Interested investors can access the webcast at this link and can arrange meetings with Mr. Haviv through the investor relations team.
Evogene Ltd. (NASDAQ: EVGN) announced that its President and CEO, Ofer Haviv, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 9-15, 2021. The presentation will take place on September 9, 2021, at 07:30 am EST, focusing on Evogene's innovative technologies and product discovery engines. Investors interested in meeting Mr. Haviv can contact Evogene's Investor Relations team. Evogene leverages its Computational Predictive Biology platform to advance life-science products in human health and agriculture.
Canonic Ltd, a subsidiary of Evogene, has announced the pre-launch of its first-generation medical cannabis products, branded as G-nnovation, in Israel. The products, which focus on high THC content, will be sold to a limited number of licensed patients through Telepharma pharmacy. Full commercial launch is expected in 2022. The Israel medical cannabis market is valued at approximately $260 million, with 100,000 licensed patients in July 2021. Canonic aims to become a global leader in medical cannabis, leveraging Evogene's advanced computational biology capabilities.
Evogene Ltd. (NASDAQ: EVGN) reported its financial results for H1 2021, revealing a cash position of $65.4 million. The company is advancing on its strategy to enhance shareholder value via its subsidiaries, considering spin-offs for independent trading. Biomica showcased significant anti-tumor activity for its candidate BMC128, with plans for a proof-of-concept trial. However, cash usage increased to $11.3 million in H1 2021, driven by product development investments, and net loss rose to $6.9 million in Q2 2021, compared to $4.8 million in Q2 2020.
Evogene Ltd. (NASDAQ: EVGN) announced that President and CEO Ofer Haviv will present at the Jefferies Virtual Industrials Conference on August 3, 2021, at 09:00 AM EST. The presentation will highlight Evogene's disruptive technologies and tailored engines for product discovery across its subsidiaries. Investors interested in meeting Mr. Haviv can contact Evogene's Investor Relations team. Evogene is focused on revolutionizing life-science product development using its Computational Predictive Biology platform, targeting sectors like human health and agriculture.
Evogene Ltd. (NASDAQ: EVGN) announces its second quarter financial results will be released on August 11, 2021. Incoming Chairperson of the Board, Ms. Sarit Firon, will discuss her vision during the conference call at 09:00 AM Eastern Time. The call can be accessed via phone or live webcast on the company's website. The replay will be available shortly after the call until August 13, 2021. Evogene focuses on life-science product development through its Computational Predictive Biology (CPB) platform, targeting sectors like human health and agriculture.
AgPlenus Ltd., a subsidiary of Evogene (NASDAQ: EVGN), announced successful results from a Proof of Concept (POC) testing of its herbicide candidate APH1, demonstrating resistance traits in modified tobacco plants. The greenhouse tests showed that these plants remained unharmed when treated with APH1, indicating potential for developing resistant commercial crops, including soybeans. This advancement is crucial as global herbicide resistance continues to rise, with the market expected to reach $34 billion in 2022. The company aims to leverage this success to broaden its offerings in crop protection.
Evogene Ltd. (NASDAQ: EVGN) has announced the appointment of Ms. Sarit Firon as the new Chairperson of the Board, pending her re-election at the upcoming Annual General Meeting. This follows the decision of Mr. Martin Gerstel, the current Chairperson, to step down after nearly 20 years. Firon, a seasoned investor with over 27 years of experience, has been on Evogene's board since 2016 and is expected to guide the company through its promising product pipelines in various life sciences markets. Both Gerstel and CEO Ofer Haviv expressed confidence in Firon's leadership capabilities.
Evogene Ltd. (NASDAQ: EVGN) announced its Q1 2021 financial results, reporting a loss of $7.1 million and an operating loss of $6.3 million, slightly improved from Q1 2020. The company retains a strong cash position with $70.1 million in reserves. Significant milestones in its subsidiaries' pipelines are anticipated in 2021-2022, including product launches and strategic collaborations, particularly with Corteva. R&D expenses decreased to $4.3 million, while G&A expenses rose to $1.5 million. Evogene aims to enhance value recognition in capital markets.